nodes	percent_of_prediction	percent_of_DWPC	metapath
Apomorphine—Injection site reaction—Gemcitabine—pancreatic cancer	0.0041	0.0106	CcSEcCtD
Apomorphine—Dehydration—Erlotinib—pancreatic cancer	0.00401	0.0103	CcSEcCtD
Apomorphine—Pain in extremity—Sunitinib—pancreatic cancer	0.00373	0.00963	CcSEcCtD
Apomorphine—Angina pectoris—Tamoxifen—pancreatic cancer	0.00367	0.00947	CcSEcCtD
Apomorphine—Rhinorrhoea—Docetaxel—pancreatic cancer	0.00361	0.00932	CcSEcCtD
Apomorphine—Dehydration—Sunitinib—pancreatic cancer	0.00347	0.00896	CcSEcCtD
Apomorphine—Pneumonia—Tamoxifen—pancreatic cancer	0.00338	0.00871	CcSEcCtD
Apomorphine—Pneumonia—Erlotinib—pancreatic cancer	0.00334	0.00862	CcSEcCtD
Apomorphine—Swelling—Fluorouracil—pancreatic cancer	0.00334	0.00861	CcSEcCtD
Apomorphine—Nasopharyngitis—Sunitinib—pancreatic cancer	0.00334	0.00861	CcSEcCtD
Apomorphine—Cardiac failure congestive—Gemcitabine—pancreatic cancer	0.0033	0.00852	CcSEcCtD
Apomorphine—Urinary tract infection—Tamoxifen—pancreatic cancer	0.00326	0.00842	CcSEcCtD
Apomorphine—Injection site reaction—Docetaxel—pancreatic cancer	0.00291	0.00751	CcSEcCtD
Apomorphine—Pneumonia—Sunitinib—pancreatic cancer	0.00289	0.00746	CcSEcCtD
Apomorphine—Dehydration—Irinotecan—pancreatic cancer	0.00286	0.00738	CcSEcCtD
Apomorphine—Orthostatic hypotension—Irinotecan—pancreatic cancer	0.00281	0.00724	CcSEcCtD
Apomorphine—Flushing—Tamoxifen—pancreatic cancer	0.0028	0.00722	CcSEcCtD
Apomorphine—Urinary tract infection—Sunitinib—pancreatic cancer	0.0028	0.00721	CcSEcCtD
Apomorphine—Nasopharyngitis—Fluorouracil—pancreatic cancer	0.00263	0.00679	CcSEcCtD
Apomorphine—Mental disorder—Erlotinib—pancreatic cancer	0.00261	0.00674	CcSEcCtD
Apomorphine—Angina pectoris—Irinotecan—pancreatic cancer	0.00259	0.00668	CcSEcCtD
Apomorphine—Sweating increased—Irinotecan—pancreatic cancer	0.00259	0.00668	CcSEcCtD
Apomorphine—Back pain—Tamoxifen—pancreatic cancer	0.00254	0.00655	CcSEcCtD
Apomorphine—Back pain—Erlotinib—pancreatic cancer	0.00251	0.00648	CcSEcCtD
Apomorphine—Angina pectoris—Fluorouracil—pancreatic cancer	0.00248	0.0064	CcSEcCtD
Apomorphine—Swelling—Docetaxel—pancreatic cancer	0.00241	0.00622	CcSEcCtD
Apomorphine—Flushing—Sunitinib—pancreatic cancer	0.0024	0.00618	CcSEcCtD
Apomorphine—Pneumonia—Irinotecan—pancreatic cancer	0.00238	0.00615	CcSEcCtD
Apomorphine—Cardiac failure congestive—Docetaxel—pancreatic cancer	0.00234	0.00605	CcSEcCtD
Apomorphine—Syncope—Erlotinib—pancreatic cancer	0.00233	0.00601	CcSEcCtD
Apomorphine—Pneumonia—Gemcitabine—pancreatic cancer	0.00232	0.00599	CcSEcCtD
Apomorphine—Pneumonia—Fluorouracil—pancreatic cancer	0.00228	0.00589	CcSEcCtD
Apomorphine—Loss of consciousness—Erlotinib—pancreatic cancer	0.00228	0.00589	CcSEcCtD
Apomorphine—Mental disorder—Sunitinib—pancreatic cancer	0.00226	0.00584	CcSEcCtD
Apomorphine—Arthralgia—Tamoxifen—pancreatic cancer	0.00223	0.00576	CcSEcCtD
Apomorphine—Chest pain—Tamoxifen—pancreatic cancer	0.00223	0.00576	CcSEcCtD
Apomorphine—Anxiety—Tamoxifen—pancreatic cancer	0.00223	0.00574	CcSEcCtD
Apomorphine—Arthralgia—Erlotinib—pancreatic cancer	0.00221	0.0057	CcSEcCtD
Apomorphine—Chest pain—Erlotinib—pancreatic cancer	0.00221	0.0057	CcSEcCtD
Apomorphine—Urinary tract infection—Fluorouracil—pancreatic cancer	0.00221	0.00569	CcSEcCtD
Apomorphine—Anxiety—Erlotinib—pancreatic cancer	0.0022	0.00568	CcSEcCtD
Apomorphine—Back pain—Sunitinib—pancreatic cancer	0.00217	0.00561	CcSEcCtD
Apomorphine—Oedema—Tamoxifen—pancreatic cancer	0.00214	0.00553	CcSEcCtD
Apomorphine—Pain in extremity—Docetaxel—pancreatic cancer	0.00213	0.00548	CcSEcCtD
Apomorphine—Oedema—Erlotinib—pancreatic cancer	0.00212	0.00547	CcSEcCtD
Apomorphine—Dyskinesia—Epirubicin—pancreatic cancer	0.0021	0.00542	CcSEcCtD
Apomorphine—Shock—Erlotinib—pancreatic cancer	0.00208	0.00538	CcSEcCtD
Apomorphine—Hyperhidrosis—Tamoxifen—pancreatic cancer	0.00207	0.00534	CcSEcCtD
Apomorphine—Dehydration—Docetaxel—pancreatic cancer	0.00198	0.0051	CcSEcCtD
Apomorphine—Flushing—Irinotecan—pancreatic cancer	0.00197	0.00509	CcSEcCtD
Apomorphine—Injection site reaction—Epirubicin—pancreatic cancer	0.00196	0.00507	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Tamoxifen—pancreatic cancer	0.00195	0.00503	CcSEcCtD
Apomorphine—Dyskinesia—Doxorubicin—pancreatic cancer	0.00194	0.00502	CcSEcCtD
Apomorphine—Orthostatic hypotension—Docetaxel—pancreatic cancer	0.00194	0.00501	CcSEcCtD
Apomorphine—Insomnia—Tamoxifen—pancreatic cancer	0.00194	0.005	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Erlotinib—pancreatic cancer	0.00193	0.00498	CcSEcCtD
Apomorphine—Insomnia—Erlotinib—pancreatic cancer	0.00192	0.00495	CcSEcCtD
Apomorphine—Arthralgia—Sunitinib—pancreatic cancer	0.00191	0.00494	CcSEcCtD
Apomorphine—Chest pain—Sunitinib—pancreatic cancer	0.00191	0.00494	CcSEcCtD
Apomorphine—Dyspnoea—Tamoxifen—pancreatic cancer	0.00191	0.00493	CcSEcCtD
Apomorphine—Nasopharyngitis—Docetaxel—pancreatic cancer	0.0019	0.0049	CcSEcCtD
Apomorphine—Dyspnoea—Erlotinib—pancreatic cancer	0.00189	0.00487	CcSEcCtD
Apomorphine—Fatigue—Tamoxifen—pancreatic cancer	0.00185	0.00476	CcSEcCtD
Apomorphine—Oedema—Sunitinib—pancreatic cancer	0.00183	0.00473	CcSEcCtD
Apomorphine—Constipation—Tamoxifen—pancreatic cancer	0.00183	0.00473	CcSEcCtD
Apomorphine—Fatigue—Erlotinib—pancreatic cancer	0.00183	0.00471	CcSEcCtD
Apomorphine—Injection site reaction—Doxorubicin—pancreatic cancer	0.00182	0.00469	CcSEcCtD
Apomorphine—Constipation—Erlotinib—pancreatic cancer	0.00181	0.00468	CcSEcCtD
Apomorphine—Shock—Sunitinib—pancreatic cancer	0.0018	0.00466	CcSEcCtD
Apomorphine—Back pain—Irinotecan—pancreatic cancer	0.00179	0.00462	CcSEcCtD
Apomorphine—Angina pectoris—Docetaxel—pancreatic cancer	0.00179	0.00462	CcSEcCtD
Apomorphine—Ecchymosis—Epirubicin—pancreatic cancer	0.00179	0.00461	CcSEcCtD
Apomorphine—Back pain—Gemcitabine—pancreatic cancer	0.00174	0.0045	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.00167	0.00431	CcSEcCtD
Apomorphine—Syncope—Irinotecan—pancreatic cancer	0.00166	0.00428	CcSEcCtD
Apomorphine—Insomnia—Sunitinib—pancreatic cancer	0.00166	0.00428	CcSEcCtD
Apomorphine—Ecchymosis—Doxorubicin—pancreatic cancer	0.00165	0.00426	CcSEcCtD
Apomorphine—Pneumonia—Docetaxel—pancreatic cancer	0.00165	0.00425	CcSEcCtD
Apomorphine—Dyspnoea—Sunitinib—pancreatic cancer	0.00164	0.00422	CcSEcCtD
Apomorphine—Loss of consciousness—Irinotecan—pancreatic cancer	0.00163	0.0042	CcSEcCtD
Apomorphine—Fatigue—Sunitinib—pancreatic cancer	0.00158	0.00408	CcSEcCtD
Apomorphine—Cardiac failure congestive—Epirubicin—pancreatic cancer	0.00158	0.00408	CcSEcCtD
Apomorphine—Constipation—Sunitinib—pancreatic cancer	0.00157	0.00405	CcSEcCtD
Apomorphine—Asthenia—Tamoxifen—pancreatic cancer	0.00154	0.00396	CcSEcCtD
Apomorphine—Arthralgia—Gemcitabine—pancreatic cancer	0.00154	0.00396	CcSEcCtD
Apomorphine—Chest pain—Gemcitabine—pancreatic cancer	0.00154	0.00396	CcSEcCtD
Apomorphine—Confusional state—Irinotecan—pancreatic cancer	0.00152	0.00393	CcSEcCtD
Apomorphine—Asthenia—Erlotinib—pancreatic cancer	0.00152	0.00392	CcSEcCtD
Apomorphine—Pruritus—Tamoxifen—pancreatic cancer	0.00152	0.00391	CcSEcCtD
Apomorphine—Oedema—Irinotecan—pancreatic cancer	0.00151	0.0039	CcSEcCtD
Apomorphine—Chest pain—Fluorouracil—pancreatic cancer	0.00151	0.0039	CcSEcCtD
Apomorphine—Pruritus—Erlotinib—pancreatic cancer	0.0015	0.00387	CcSEcCtD
Apomorphine—Shock—Irinotecan—pancreatic cancer	0.00149	0.00384	CcSEcCtD
Apomorphine—Oedema—Gemcitabine—pancreatic cancer	0.00147	0.0038	CcSEcCtD
Apomorphine—Diarrhoea—Tamoxifen—pancreatic cancer	0.00147	0.00378	CcSEcCtD
Apomorphine—Cardiac failure congestive—Doxorubicin—pancreatic cancer	0.00146	0.00377	CcSEcCtD
Apomorphine—Hyperhidrosis—Irinotecan—pancreatic cancer	0.00146	0.00377	CcSEcCtD
Apomorphine—Confusional state—Fluorouracil—pancreatic cancer	0.00146	0.00377	CcSEcCtD
Apomorphine—Diarrhoea—Erlotinib—pancreatic cancer	0.00145	0.00374	CcSEcCtD
Apomorphine—Oedema—Fluorouracil—pancreatic cancer	0.00145	0.00373	CcSEcCtD
Apomorphine—Pain in extremity—Epirubicin—pancreatic cancer	0.00143	0.0037	CcSEcCtD
Apomorphine—Hyperhidrosis—Gemcitabine—pancreatic cancer	0.00142	0.00367	CcSEcCtD
Apomorphine—Dizziness—Tamoxifen—pancreatic cancer	0.00142	0.00365	CcSEcCtD
Apomorphine—Hypotension—Irinotecan—pancreatic cancer	0.00141	0.00364	CcSEcCtD
Apomorphine—Dizziness—Erlotinib—pancreatic cancer	0.0014	0.00362	CcSEcCtD
Apomorphine—Hypotension—Gemcitabine—pancreatic cancer	0.00138	0.00355	CcSEcCtD
Apomorphine—Insomnia—Irinotecan—pancreatic cancer	0.00137	0.00353	CcSEcCtD
Apomorphine—Flushing—Docetaxel—pancreatic cancer	0.00136	0.00352	CcSEcCtD
Apomorphine—Vomiting—Tamoxifen—pancreatic cancer	0.00136	0.00351	CcSEcCtD
Apomorphine—Hypotension—Fluorouracil—pancreatic cancer	0.00135	0.00349	CcSEcCtD
Apomorphine—Vomiting—Erlotinib—pancreatic cancer	0.00135	0.00348	CcSEcCtD
Apomorphine—Dyspnoea—Irinotecan—pancreatic cancer	0.00135	0.00348	CcSEcCtD
Apomorphine—Somnolence—Irinotecan—pancreatic cancer	0.00134	0.00347	CcSEcCtD
Apomorphine—Headache—Tamoxifen—pancreatic cancer	0.00134	0.00346	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.00134	0.00346	CcSEcCtD
Apomorphine—Dehydration—Epirubicin—pancreatic cancer	0.00133	0.00344	CcSEcCtD
Apomorphine—Insomnia—Gemcitabine—pancreatic cancer	0.00133	0.00343	CcSEcCtD
Apomorphine—Headache—Erlotinib—pancreatic cancer	0.00133	0.00343	CcSEcCtD
Apomorphine—Pain in extremity—Doxorubicin—pancreatic cancer	0.00133	0.00342	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.00132	0.0034	CcSEcCtD
Apomorphine—Asthenia—Sunitinib—pancreatic cancer	0.00132	0.0034	CcSEcCtD
Apomorphine—Dyspnoea—Gemcitabine—pancreatic cancer	0.00131	0.00339	CcSEcCtD
Apomorphine—Orthostatic hypotension—Epirubicin—pancreatic cancer	0.00131	0.00338	CcSEcCtD
Apomorphine—Insomnia—Fluorouracil—pancreatic cancer	0.00131	0.00338	CcSEcCtD
Apomorphine—Somnolence—Gemcitabine—pancreatic cancer	0.00131	0.00338	CcSEcCtD
Apomorphine—Fatigue—Irinotecan—pancreatic cancer	0.0013	0.00336	CcSEcCtD
Apomorphine—Pruritus—Sunitinib—pancreatic cancer	0.0013	0.00335	CcSEcCtD
Apomorphine—Constipation—Irinotecan—pancreatic cancer	0.00129	0.00333	CcSEcCtD
Apomorphine—Dyspnoea—Fluorouracil—pancreatic cancer	0.00129	0.00333	CcSEcCtD
Apomorphine—Mental disorder—Docetaxel—pancreatic cancer	0.00129	0.00332	CcSEcCtD
Apomorphine—Somnolence—Fluorouracil—pancreatic cancer	0.00129	0.00332	CcSEcCtD
Apomorphine—Nasopharyngitis—Epirubicin—pancreatic cancer	0.00128	0.00331	CcSEcCtD
Apomorphine—Nausea—Tamoxifen—pancreatic cancer	0.00127	0.00328	CcSEcCtD
Apomorphine—Fatigue—Gemcitabine—pancreatic cancer	0.00127	0.00327	CcSEcCtD
Apomorphine—Constipation—Gemcitabine—pancreatic cancer	0.00126	0.00325	CcSEcCtD
Apomorphine—Nausea—Erlotinib—pancreatic cancer	0.00126	0.00325	CcSEcCtD
Apomorphine—Diarrhoea—Sunitinib—pancreatic cancer	0.00126	0.00324	CcSEcCtD
Apomorphine—Feeling abnormal—Irinotecan—pancreatic cancer	0.00125	0.00321	CcSEcCtD
Apomorphine—Back pain—Docetaxel—pancreatic cancer	0.00124	0.00319	CcSEcCtD
Apomorphine—Dehydration—Doxorubicin—pancreatic cancer	0.00123	0.00318	CcSEcCtD
Apomorphine—Dizziness—Sunitinib—pancreatic cancer	0.00121	0.00313	CcSEcCtD
Apomorphine—Feeling abnormal—Gemcitabine—pancreatic cancer	0.00121	0.00313	CcSEcCtD
Apomorphine—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.00121	0.00313	CcSEcCtD
Apomorphine—Angina pectoris—Epirubicin—pancreatic cancer	0.00121	0.00311	CcSEcCtD
Apomorphine—Feeling abnormal—Fluorouracil—pancreatic cancer	0.00119	0.00308	CcSEcCtD
Apomorphine—Nasopharyngitis—Doxorubicin—pancreatic cancer	0.00119	0.00306	CcSEcCtD
Apomorphine—Vomiting—Sunitinib—pancreatic cancer	0.00117	0.00301	CcSEcCtD
Apomorphine—Headache—Sunitinib—pancreatic cancer	0.00115	0.00297	CcSEcCtD
Apomorphine—Syncope—Docetaxel—pancreatic cancer	0.00115	0.00296	CcSEcCtD
Apomorphine—Loss of consciousness—Docetaxel—pancreatic cancer	0.00112	0.0029	CcSEcCtD
Apomorphine—Angina pectoris—Doxorubicin—pancreatic cancer	0.00112	0.00288	CcSEcCtD
Apomorphine—Pneumonia—Epirubicin—pancreatic cancer	0.00111	0.00287	CcSEcCtD
Apomorphine—Drowsiness—Epirubicin—pancreatic cancer	0.0011	0.00285	CcSEcCtD
Apomorphine—Chest pain—Docetaxel—pancreatic cancer	0.00109	0.00281	CcSEcCtD
Apomorphine—Arthralgia—Docetaxel—pancreatic cancer	0.00109	0.00281	CcSEcCtD
Apomorphine—Nausea—Sunitinib—pancreatic cancer	0.00109	0.00281	CcSEcCtD
Apomorphine—Asthenia—Irinotecan—pancreatic cancer	0.00108	0.0028	CcSEcCtD
Apomorphine—Urinary tract infection—Epirubicin—pancreatic cancer	0.00107	0.00277	CcSEcCtD
Apomorphine—Asthenia—Gemcitabine—pancreatic cancer	0.00106	0.00272	CcSEcCtD
Apomorphine—Confusional state—Docetaxel—pancreatic cancer	0.00105	0.00272	CcSEcCtD
Apomorphine—Oedema—Docetaxel—pancreatic cancer	0.00104	0.0027	CcSEcCtD
Apomorphine—Pruritus—Gemcitabine—pancreatic cancer	0.00104	0.00269	CcSEcCtD
Apomorphine—Diarrhoea—Irinotecan—pancreatic cancer	0.00103	0.00267	CcSEcCtD
Apomorphine—Pneumonia—Doxorubicin—pancreatic cancer	0.00103	0.00265	CcSEcCtD
Apomorphine—Shock—Docetaxel—pancreatic cancer	0.00103	0.00265	CcSEcCtD
Apomorphine—Pruritus—Fluorouracil—pancreatic cancer	0.00102	0.00264	CcSEcCtD
Apomorphine—Drowsiness—Doxorubicin—pancreatic cancer	0.00102	0.00264	CcSEcCtD
Apomorphine—Diarrhoea—Gemcitabine—pancreatic cancer	0.00101	0.0026	CcSEcCtD
Apomorphine—Dizziness—Irinotecan—pancreatic cancer	0.000999	0.00258	CcSEcCtD
Apomorphine—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000993	0.00256	CcSEcCtD
Apomorphine—Diarrhoea—Fluorouracil—pancreatic cancer	0.00099	0.00255	CcSEcCtD
Apomorphine—Hypotension—Docetaxel—pancreatic cancer	0.000976	0.00252	CcSEcCtD
Apomorphine—Vomiting—Irinotecan—pancreatic cancer	0.000961	0.00248	CcSEcCtD
Apomorphine—Dizziness—Fluorouracil—pancreatic cancer	0.000957	0.00247	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000952	0.00246	CcSEcCtD
Apomorphine—Headache—Irinotecan—pancreatic cancer	0.000947	0.00244	CcSEcCtD
Apomorphine—Insomnia—Docetaxel—pancreatic cancer	0.000945	0.00244	CcSEcCtD
Apomorphine—Vomiting—Gemcitabine—pancreatic cancer	0.000936	0.00241	CcSEcCtD
Apomorphine—Dyspnoea—Docetaxel—pancreatic cancer	0.000931	0.0024	CcSEcCtD
Apomorphine—Somnolence—Docetaxel—pancreatic cancer	0.000929	0.0024	CcSEcCtD
Apomorphine—Headache—Gemcitabine—pancreatic cancer	0.000922	0.00238	CcSEcCtD
Apomorphine—Flushing—Epirubicin—pancreatic cancer	0.00092	0.00237	CcSEcCtD
Apomorphine—Vomiting—Fluorouracil—pancreatic cancer	0.00092	0.00237	CcSEcCtD
Apomorphine—Headache—Fluorouracil—pancreatic cancer	0.000907	0.00234	CcSEcCtD
Apomorphine—Fatigue—Docetaxel—pancreatic cancer	0.0009	0.00232	CcSEcCtD
Apomorphine—Nausea—Irinotecan—pancreatic cancer	0.000897	0.00232	CcSEcCtD
Apomorphine—Constipation—Docetaxel—pancreatic cancer	0.000893	0.0023	CcSEcCtD
Apomorphine—Nausea—Gemcitabine—pancreatic cancer	0.000874	0.00226	CcSEcCtD
Apomorphine—Mental disorder—Epirubicin—pancreatic cancer	0.000869	0.00224	CcSEcCtD
Apomorphine—Feeling abnormal—Docetaxel—pancreatic cancer	0.000861	0.00222	CcSEcCtD
Apomorphine—Nausea—Fluorouracil—pancreatic cancer	0.00086	0.00222	CcSEcCtD
Apomorphine—Flushing—Doxorubicin—pancreatic cancer	0.000852	0.0022	CcSEcCtD
Apomorphine—Back pain—Epirubicin—pancreatic cancer	0.000835	0.00215	CcSEcCtD
Apomorphine—Mental disorder—Doxorubicin—pancreatic cancer	0.000804	0.00207	CcSEcCtD
Apomorphine—Syncope—Epirubicin—pancreatic cancer	0.000774	0.002	CcSEcCtD
Apomorphine—Back pain—Doxorubicin—pancreatic cancer	0.000773	0.00199	CcSEcCtD
Apomorphine—Loss of consciousness—Epirubicin—pancreatic cancer	0.000759	0.00196	CcSEcCtD
Apomorphine—Asthenia—Docetaxel—pancreatic cancer	0.000749	0.00193	CcSEcCtD
Apomorphine—Pruritus—Docetaxel—pancreatic cancer	0.000739	0.00191	CcSEcCtD
Apomorphine—Chest pain—Epirubicin—pancreatic cancer	0.000735	0.0019	CcSEcCtD
Apomorphine—Arthralgia—Epirubicin—pancreatic cancer	0.000735	0.0019	CcSEcCtD
Apomorphine—Anxiety—Epirubicin—pancreatic cancer	0.000732	0.00189	CcSEcCtD
Apomorphine—Syncope—Doxorubicin—pancreatic cancer	0.000716	0.00185	CcSEcCtD
Apomorphine—Diarrhoea—Docetaxel—pancreatic cancer	0.000715	0.00184	CcSEcCtD
Apomorphine—Confusional state—Epirubicin—pancreatic cancer	0.00071	0.00183	CcSEcCtD
Apomorphine—Oedema—Epirubicin—pancreatic cancer	0.000704	0.00182	CcSEcCtD
Apomorphine—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000702	0.00181	CcSEcCtD
Apomorphine—Shock—Epirubicin—pancreatic cancer	0.000693	0.00179	CcSEcCtD
Apomorphine—Dizziness—Docetaxel—pancreatic cancer	0.000691	0.00178	CcSEcCtD
Apomorphine—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000681	0.00176	CcSEcCtD
Apomorphine—Arthralgia—Doxorubicin—pancreatic cancer	0.00068	0.00175	CcSEcCtD
Apomorphine—Chest pain—Doxorubicin—pancreatic cancer	0.00068	0.00175	CcSEcCtD
Apomorphine—Anxiety—Doxorubicin—pancreatic cancer	0.000678	0.00175	CcSEcCtD
Apomorphine—Vomiting—Docetaxel—pancreatic cancer	0.000664	0.00171	CcSEcCtD
Apomorphine—Hypotension—Epirubicin—pancreatic cancer	0.000658	0.0017	CcSEcCtD
Apomorphine—Confusional state—Doxorubicin—pancreatic cancer	0.000657	0.0017	CcSEcCtD
Apomorphine—Headache—Docetaxel—pancreatic cancer	0.000654	0.00169	CcSEcCtD
Apomorphine—Oedema—Doxorubicin—pancreatic cancer	0.000652	0.00168	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000642	0.00166	CcSEcCtD
Apomorphine—Shock—Doxorubicin—pancreatic cancer	0.000641	0.00165	CcSEcCtD
Apomorphine—Insomnia—Epirubicin—pancreatic cancer	0.000637	0.00164	CcSEcCtD
Apomorphine—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.00063	0.00163	CcSEcCtD
Apomorphine—Dyspnoea—Epirubicin—pancreatic cancer	0.000628	0.00162	CcSEcCtD
Apomorphine—Somnolence—Epirubicin—pancreatic cancer	0.000626	0.00162	CcSEcCtD
Apomorphine—Nausea—Docetaxel—pancreatic cancer	0.00062	0.0016	CcSEcCtD
Apomorphine—Hypotension—Doxorubicin—pancreatic cancer	0.000609	0.00157	CcSEcCtD
Apomorphine—Fatigue—Epirubicin—pancreatic cancer	0.000607	0.00157	CcSEcCtD
Apomorphine—Constipation—Epirubicin—pancreatic cancer	0.000602	0.00155	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000594	0.00153	CcSEcCtD
Apomorphine—Insomnia—Doxorubicin—pancreatic cancer	0.00059	0.00152	CcSEcCtD
Apomorphine—Dyspnoea—Doxorubicin—pancreatic cancer	0.000581	0.0015	CcSEcCtD
Apomorphine—Feeling abnormal—Epirubicin—pancreatic cancer	0.000581	0.0015	CcSEcCtD
Apomorphine—Somnolence—Doxorubicin—pancreatic cancer	0.000579	0.0015	CcSEcCtD
Apomorphine—Fatigue—Doxorubicin—pancreatic cancer	0.000562	0.00145	CcSEcCtD
Apomorphine—Constipation—Doxorubicin—pancreatic cancer	0.000557	0.00144	CcSEcCtD
Apomorphine—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000537	0.00139	CcSEcCtD
Apomorphine—Asthenia—Epirubicin—pancreatic cancer	0.000505	0.0013	CcSEcCtD
Apomorphine—Pruritus—Epirubicin—pancreatic cancer	0.000498	0.00129	CcSEcCtD
Apomorphine—Diarrhoea—Epirubicin—pancreatic cancer	0.000482	0.00124	CcSEcCtD
Apomorphine—Asthenia—Doxorubicin—pancreatic cancer	0.000468	0.00121	CcSEcCtD
Apomorphine—Dizziness—Epirubicin—pancreatic cancer	0.000466	0.0012	CcSEcCtD
Apomorphine—Pruritus—Doxorubicin—pancreatic cancer	0.000461	0.00119	CcSEcCtD
Apomorphine—Vomiting—Epirubicin—pancreatic cancer	0.000448	0.00116	CcSEcCtD
Apomorphine—Diarrhoea—Doxorubicin—pancreatic cancer	0.000446	0.00115	CcSEcCtD
Apomorphine—Headache—Epirubicin—pancreatic cancer	0.000441	0.00114	CcSEcCtD
Apomorphine—Dizziness—Doxorubicin—pancreatic cancer	0.000431	0.00111	CcSEcCtD
Apomorphine—Nausea—Epirubicin—pancreatic cancer	0.000418	0.00108	CcSEcCtD
Apomorphine—Vomiting—Doxorubicin—pancreatic cancer	0.000414	0.00107	CcSEcCtD
Apomorphine—Headache—Doxorubicin—pancreatic cancer	0.000408	0.00105	CcSEcCtD
Apomorphine—Nausea—Doxorubicin—pancreatic cancer	0.000387	0.000999	CcSEcCtD
Apomorphine—HTR1A—Signaling by GPCR—HRAS—pancreatic cancer	2.49e-05	4.06e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—STAT3—pancreatic cancer	2.48e-05	4.05e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—CASP3—pancreatic cancer	2.48e-05	4.05e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—PIK3CB—pancreatic cancer	2.48e-05	4.05e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—NRAS—pancreatic cancer	2.48e-05	4.04e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling by GPCR—HRAS—pancreatic cancer	2.47e-05	4.04e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—MYC—pancreatic cancer	2.45e-05	4.01e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—EGFR—pancreatic cancer	2.45e-05	4e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—TGFB1—pancreatic cancer	2.45e-05	4e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—PIK3CB—pancreatic cancer	2.45e-05	4e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—EGFR—pancreatic cancer	2.43e-05	3.97e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—SRC—pancreatic cancer	2.43e-05	3.96e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—PTGS2—pancreatic cancer	2.42e-05	3.96e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—CXCL8—pancreatic cancer	2.42e-05	3.95e-05	CbGpPWpGaD
Apomorphine—HTR1A—GPCR downstream signaling—AKT1—pancreatic cancer	2.42e-05	3.95e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—MYC—pancreatic cancer	2.42e-05	3.94e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—CCND1—pancreatic cancer	2.41e-05	3.94e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—TGFB1—pancreatic cancer	2.41e-05	3.93e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling by GPCR—HRAS—pancreatic cancer	2.41e-05	3.93e-05	CbGpPWpGaD
Apomorphine—HTR2C—GPCR downstream signaling—AKT1—pancreatic cancer	2.4e-05	3.93e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—EGFR—pancreatic cancer	2.4e-05	3.92e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—CASP3—pancreatic cancer	2.39e-05	3.91e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—SRC—pancreatic cancer	2.39e-05	3.91e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—SRC—pancreatic cancer	2.39e-05	3.91e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—CTNNB1—pancreatic cancer	2.39e-05	3.9e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—CXCL8—pancreatic cancer	2.38e-05	3.89e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—CASP3—pancreatic cancer	2.38e-05	3.89e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling by GPCR—HRAS—pancreatic cancer	2.37e-05	3.87e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—VEGFA—pancreatic cancer	2.36e-05	3.86e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—EGFR—pancreatic cancer	2.36e-05	3.86e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling by GPCR—PIK3CA—pancreatic cancer	2.36e-05	3.85e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—PIK3CD—pancreatic cancer	2.35e-05	3.83e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—MMP9—pancreatic cancer	2.34e-05	3.83e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—STAT3—pancreatic cancer	2.34e-05	3.82e-05	CbGpPWpGaD
Apomorphine—ADRA2C—GPCR downstream signaling—AKT1—pancreatic cancer	2.34e-05	3.82e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—NRAS—pancreatic cancer	2.33e-05	3.81e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—VEGFA—pancreatic cancer	2.33e-05	3.81e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—VEGFA—pancreatic cancer	2.33e-05	3.81e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—CCND1—pancreatic cancer	2.33e-05	3.81e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—PTEN—pancreatic cancer	2.33e-05	3.81e-05	CbGpPWpGaD
Apomorphine—ADRA2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	2.33e-05	3.8e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling by GPCR—PIK3CA—pancreatic cancer	2.32e-05	3.79e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—CCND1—pancreatic cancer	2.32e-05	3.79e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—CASP3—pancreatic cancer	2.32e-05	3.78e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—KRAS—pancreatic cancer	2.32e-05	3.78e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—STAT3—pancreatic cancer	2.31e-05	3.77e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—STAT3—pancreatic cancer	2.31e-05	3.77e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—CTNNB1—pancreatic cancer	2.31e-05	3.77e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—MYC—pancreatic cancer	2.31e-05	3.76e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—NRAS—pancreatic cancer	2.3e-05	3.76e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—NRAS—pancreatic cancer	2.3e-05	3.76e-05	CbGpPWpGaD
Apomorphine—ADRA1B—GPCR downstream signaling—AKT1—pancreatic cancer	2.3e-05	3.76e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—TGFB1—pancreatic cancer	2.3e-05	3.76e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—KRAS—pancreatic cancer	2.3e-05	3.75e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—CTNNB1—pancreatic cancer	2.3e-05	3.75e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—PIK3CB—pancreatic cancer	2.29e-05	3.73e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—CASP3—pancreatic cancer	2.28e-05	3.72e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling by GPCR—AKT1—pancreatic cancer	2.27e-05	3.71e-05	CbGpPWpGaD
Apomorphine—DRD5—Signaling Pathways—AKT1—pancreatic cancer	2.27e-05	3.71e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—KRAS—pancreatic cancer	2.27e-05	3.7e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—MMP9—pancreatic cancer	2.26e-05	3.7e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—CCND1—pancreatic cancer	2.26e-05	3.68e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—EGFR—pancreatic cancer	2.26e-05	3.68e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—MMP9—pancreatic cancer	2.25e-05	3.68e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—PTEN—pancreatic cancer	2.25e-05	3.67e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—PIK3CB—pancreatic cancer	2.25e-05	3.67e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—PTEN—pancreatic cancer	2.24e-05	3.65e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—CTNNB1—pancreatic cancer	2.23e-05	3.65e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—KRAS—pancreatic cancer	2.23e-05	3.64e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—CCND1—pancreatic cancer	2.22e-05	3.62e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—CTNNB1—pancreatic cancer	2.2e-05	3.59e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CXCL8—pancreatic cancer	2.2e-05	3.59e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling by GPCR—AKT1—pancreatic cancer	2.19e-05	3.58e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—MMP9—pancreatic cancer	2.19e-05	3.58e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling by GPCR—AKT1—pancreatic cancer	2.18e-05	3.57e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling by GPCR—HRAS—pancreatic cancer	2.18e-05	3.56e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—PTEN—pancreatic cancer	2.18e-05	3.55e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—MYC—pancreatic cancer	2.17e-05	3.55e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—TGFB1—pancreatic cancer	2.17e-05	3.54e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CXCL8—pancreatic cancer	2.16e-05	3.53e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—SRC—pancreatic cancer	2.16e-05	3.53e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—MMP9—pancreatic cancer	2.16e-05	3.52e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling by GPCR—HRAS—pancreatic cancer	2.15e-05	3.51e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—MYC—pancreatic cancer	2.15e-05	3.5e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—MYC—pancreatic cancer	2.15e-05	3.5e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—PTEN—pancreatic cancer	2.14e-05	3.5e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—TGFB1—pancreatic cancer	2.14e-05	3.49e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—TGFB1—pancreatic cancer	2.14e-05	3.49e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—KRAS—pancreatic cancer	2.13e-05	3.48e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—PIK3CA—pancreatic cancer	2.13e-05	3.47e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—EGFR—pancreatic cancer	2.13e-05	3.47e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling by GPCR—AKT1—pancreatic cancer	2.12e-05	3.47e-05	CbGpPWpGaD
Apomorphine—DRD2—GPCR downstream signaling—AKT1—pancreatic cancer	2.12e-05	3.46e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—PTEN—pancreatic cancer	2.11e-05	3.45e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	2.11e-05	3.45e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—VEGFA—pancreatic cancer	2.11e-05	3.44e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CASP3—pancreatic cancer	2.1e-05	3.43e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—EGFR—pancreatic cancer	2.1e-05	3.43e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—EGFR—pancreatic cancer	2.1e-05	3.43e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling by GPCR—AKT1—pancreatic cancer	2.09e-05	3.41e-05	CbGpPWpGaD
Apomorphine—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	2.09e-05	3.41e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—SRC—pancreatic cancer	2.09e-05	3.41e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—STAT3—pancreatic cancer	2.08e-05	3.4e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—PIK3CA—pancreatic cancer	2.08e-05	3.4e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—NRAS—pancreatic cancer	2.08e-05	3.4e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—SRC—pancreatic cancer	2.08e-05	3.39e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	2.07e-05	3.38e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—TP53—pancreatic cancer	2.06e-05	3.36e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—PIK3CA—pancreatic cancer	2.05e-05	3.35e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CCND1—pancreatic cancer	2.05e-05	3.34e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	2.05e-05	3.34e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	2.03e-05	3.32e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CTNNB1—pancreatic cancer	2.03e-05	3.31e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	2.02e-05	3.3e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—SRC—pancreatic cancer	2.02e-05	3.3e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—TP53—pancreatic cancer	2.02e-05	3.29e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	2.01e-05	3.29e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	2.01e-05	3.29e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—KRAS—pancreatic cancer	2.01e-05	3.28e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	2.01e-05	3.28e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	2e-05	3.27e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	2e-05	3.26e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	1.99e-05	3.26e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—SRC—pancreatic cancer	1.99e-05	3.24e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—MMP9—pancreatic cancer	1.99e-05	3.24e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—TP53—pancreatic cancer	1.98e-05	3.24e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—KRAS—pancreatic cancer	1.98e-05	3.24e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—KRAS—pancreatic cancer	1.98e-05	3.24e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—PTEN—pancreatic cancer	1.98e-05	3.23e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—HRAS—pancreatic cancer	1.97e-05	3.21e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	1.97e-05	3.21e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—VEGFA—pancreatic cancer	1.97e-05	3.21e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—PIK3CA—pancreatic cancer	1.96e-05	3.2e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	1.96e-05	3.19e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	1.95e-05	3.19e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—STAT3—pancreatic cancer	1.95e-05	3.18e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	1.94e-05	3.17e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—NRAS—pancreatic cancer	1.94e-05	3.17e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—MYC—pancreatic cancer	1.94e-05	3.16e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—VEGFA—pancreatic cancer	1.94e-05	3.16e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—TGFB1—pancreatic cancer	1.93e-05	3.15e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—HRAS—pancreatic cancer	1.93e-05	3.15e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling by GPCR—AKT1—pancreatic cancer	1.93e-05	3.15e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—STAT3—pancreatic cancer	1.92e-05	3.13e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—NRAS—pancreatic cancer	1.91e-05	3.12e-05	CbGpPWpGaD
Apomorphine—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	1.9e-05	3.1e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—HRAS—pancreatic cancer	1.9e-05	3.1e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	1.9e-05	3.1e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—EGFR—pancreatic cancer	1.89e-05	3.09e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—TP53—pancreatic cancer	1.89e-05	3.09e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	1.88e-05	3.07e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—MYC—pancreatic cancer	1.87e-05	3.05e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	1.87e-05	3.05e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—MYC—pancreatic cancer	1.86e-05	3.04e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	1.86e-05	3.03e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—PIK3CA—pancreatic cancer	1.85e-05	3.01e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Metabolism—PIK3CA—pancreatic cancer	1.84e-05	3e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	1.83e-05	2.99e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—SRC—pancreatic cancer	1.83e-05	2.99e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	1.83e-05	2.99e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—PIK3CA—pancreatic cancer	1.82e-05	2.97e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—PIK3CA—pancreatic cancer	1.82e-05	2.97e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	1.82e-05	2.97e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	1.81e-05	2.96e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—HRAS—pancreatic cancer	1.81e-05	2.96e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—MYC—pancreatic cancer	1.81e-05	2.95e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—TGFB1—pancreatic cancer	1.8e-05	2.95e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—SRC—pancreatic cancer	1.8e-05	2.94e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—KRAS—pancreatic cancer	1.79e-05	2.92e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—TP53—pancreatic cancer	1.79e-05	2.92e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—VEGFA—pancreatic cancer	1.78e-05	2.91e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—MYC—pancreatic cancer	1.78e-05	2.91e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	1.78e-05	2.9e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—TGFB1—pancreatic cancer	1.78e-05	2.9e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—EGFR—pancreatic cancer	1.77e-05	2.89e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	1.77e-05	2.89e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—STAT3—pancreatic cancer	1.77e-05	2.88e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—NRAS—pancreatic cancer	1.76e-05	2.88e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—TP53—pancreatic cancer	1.76e-05	2.88e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—TP53—pancreatic cancer	1.76e-05	2.88e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	1.76e-05	2.87e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—EGFR—pancreatic cancer	1.74e-05	2.84e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	1.74e-05	2.84e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—AKT1—pancreatic cancer	1.74e-05	2.84e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	1.73e-05	2.83e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	1.73e-05	2.82e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	1.73e-05	2.82e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	1.72e-05	2.81e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—HRAS—pancreatic cancer	1.71e-05	2.79e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—AKT1—pancreatic cancer	1.7e-05	2.78e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—HRAS—pancreatic cancer	1.68e-05	2.75e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—HRAS—pancreatic cancer	1.68e-05	2.75e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—AKT1—pancreatic cancer	1.67e-05	2.73e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—KRAS—pancreatic cancer	1.67e-05	2.73e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—KRAS—pancreatic cancer	1.65e-05	2.69e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—PIK3CA—pancreatic cancer	1.64e-05	2.68e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—MYC—pancreatic cancer	1.64e-05	2.68e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	1.64e-05	2.68e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—TGFB1—pancreatic cancer	1.64e-05	2.67e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—MYC—pancreatic cancer	1.62e-05	2.64e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	1.61e-05	2.63e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—EGFR—pancreatic cancer	1.61e-05	2.62e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—AKT1—pancreatic cancer	1.6e-05	2.61e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	1.6e-05	2.61e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—TP53—pancreatic cancer	1.59e-05	2.6e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	1.59e-05	2.59e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	1.58e-05	2.58e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	1.58e-05	2.58e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	1.58e-05	2.58e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	1.58e-05	2.58e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—PIK3CA—pancreatic cancer	1.54e-05	2.51e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—TP53—pancreatic cancer	1.54e-05	2.51e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—TP53—pancreatic cancer	1.53e-05	2.49e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—HRAS—pancreatic cancer	1.52e-05	2.48e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—KRAS—pancreatic cancer	1.52e-05	2.48e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—PIK3CA—pancreatic cancer	1.51e-05	2.47e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—AKT1—pancreatic cancer	1.51e-05	2.46e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Metabolism—AKT1—pancreatic cancer	1.5e-05	2.45e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	1.49e-05	2.44e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	1.49e-05	2.44e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—AKT1—pancreatic cancer	1.49e-05	2.43e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—AKT1—pancreatic cancer	1.49e-05	2.43e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—TP53—pancreatic cancer	1.49e-05	2.43e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	1.47e-05	2.4e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	1.47e-05	2.4e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	1.47e-05	2.39e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—TP53—pancreatic cancer	1.46e-05	2.39e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	1.46e-05	2.39e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	1.44e-05	2.35e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—HRAS—pancreatic cancer	1.42e-05	2.32e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—HRAS—pancreatic cancer	1.4e-05	2.28e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—PIK3CA—pancreatic cancer	1.39e-05	2.28e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	1.37e-05	2.24e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	1.36e-05	2.22e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—TP53—pancreatic cancer	1.35e-05	2.2e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—AKT1—pancreatic cancer	1.34e-05	2.19e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—TP53—pancreatic cancer	1.33e-05	2.17e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	1.3e-05	2.12e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	1.29e-05	2.11e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—HRAS—pancreatic cancer	1.29e-05	2.11e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	1.27e-05	2.07e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—AKT1—pancreatic cancer	1.25e-05	2.05e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	1.25e-05	2.04e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—AKT1—pancreatic cancer	1.23e-05	2.02e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—AKT1—pancreatic cancer	1.22e-05	1.99e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	1.21e-05	1.97e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	1.15e-05	1.88e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—AKT1—pancreatic cancer	1.14e-05	1.86e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	1.12e-05	1.83e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	1.02e-05	1.66e-05	CbGpPWpGaD
